Phase 4
N=62
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Influenza, Human · Transplantation Infection
Bottom Line
View on ClinicalTrials.gov: NCT01808456 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Number of Patients With Local Site Reactions — 2; 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- influenza trivalent inactive vaccine (Biological); influenza trivalent inactive vaccine high dose (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Inova Health Care Services
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Local Site Reactions |
2; 2 | — |
| PRIMARY Measurement of Strain-specific Hemagglutination Inhibition (HI) Antibody Titers |
14; 19; 16; 23; 15; 21 | — |
| SECONDARY All Cause ED Visits/Unscheduled Clinic Visits |
30; 25 | — |
| SECONDARY Number and Percentage of Subjects in Each Group Achieving Seroconversion for Each Strain |
7; 6; 7; 7 | — |
Summary
Influenza infection in recipients of solid organ transplants recipients while on maintenance immunosuppressant therapy is associated with increased morbidity and mortality. Although influenza vaccination is recommended in these high-risk patients, safety and immunogenicity of commercially available different strengths of influenza vaccine have not been established.
The primary study objective is to determine the safety and immunogenicity of Fluzone and Fluzone High-Dose, with a secondary objective to determine the tolerability and efficacy of two different strengths of trivalent influenza vaccine (TIV, flu vaccine). Both vaccines are commercially available for use in the general population. Fluzone is approved for use in 6 months of age and older, and Fluzone High-Dose is approved for use in 65 years of age and older.
This is an exploratory, open-label, parallel group, observer blinded, prospective study. All recipients of kidney, lung, heart transplants who attend for post-transplant follow-up, at least 30-days after transplantation at Inova Fairfax Hospital Transplant Center will be eligible for enrollment.
Enrolled patients will be followed for three months (a total of 4 visits) following enrollment and randomization: day 0 (enrollment) and follow-up visits at weeks 1, 4, 8, and 12.
Eligibility Criteria
Inclusion Criteria
- All adults age ≥18 years of age following solid organ transplants (kidney, heart and lung) of all races and gender unless as specified in the exclusion criteria.
- At least 30 days after organ transplantation of kidney, heart, or lung.
- In good health as determined by a) medical history, b) physical examinations, c) clinical judgment of the investigator team.
- Informed consent will be obtained from all the subjects before enrollment into the study, after the nature of the study has been fully explained to the satisfaction of the participant.
- Non-English speaking persons will be included ONLY if consent can be obtained with the help of the translator or interpreter.
Exclusion Criteria
- Less than 30 days after transplantation procedure.
- Post operative complications of any type.
- Transplant organ dysfunction and/or under evaluation for possible infection.
- Recent acute transplant rejection and treatment for rejection for the past 30 days.
- Receiving another investigational drug or biologic for transplant.
- Previous history of allergic reaction to influenza vaccine, chicken egg or other unknown allergic reactions to flu vaccine or other vaccines.
- Acute ongoing respiratory illness.
- Bleeding diathesis or on anticoagulation therapy.
- Major surgery (pre-arranged) planned during the study period.
- Any condition that may preclude the participant from completion of study related activities; such as planned travel, or out of the state of residence and not able to return for follow-up visits or relocation of residence.
- Females of reproductive age unless proven to be urine HCG negative at the time of participation.
- Recent opportunistic infection, such as CMV, EBV, BK viral reactivation, or any other documented or laboratory confirmed opportunistic infection or on treatment for confirmed infection.
- Vulnerable subjects such as aged less than 18 years, pregnant women, nursing home residents or other institutionalized persons, students, employees, prisoners, and persons who may not be able to make independent decisions or is considered to have a cognitive impairment, or non-English speaking in the absence of a reliable interpreter or translator.
Data sourced from ClinicalTrials.gov (NCT01808456). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.